{"name":"Prestige BioPharma","slug":"prestige-biopharma","ticker":"PBP","exchange":"SGX","domain":"prestigebiopharma.com","description":"Prestige BioPharma (PBP) is a biopharmaceutical company focused on developing and commercializing biosimilars and biologics. The company has a strong pipeline of products, including a biosimilar to a leading biologic. PBP is positioned to capitalize on the growing demand for biosimilars and biologics in the global market.","hq":"Singapore","founded":2015,"employees":"~2,500","ceo":"Lisa S. Park","sector":"Biosimilars / Biologics","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"153400000000","metrics":{"revenue":180000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Biosimilar to Humira patent cliff ($1.5B at risk)","drug":"Biosimilar to Humira","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"HD204","genericName":"HD204","slug":"hd204","indication":"Type 2 diabetes","status":"phase_3"},{"name":"HD201","genericName":"HD201","slug":"hd201","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"HD204","genericName":"HD204","slug":"hd204","phase":"phase_3","mechanism":"HD204 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"HD201","genericName":"HD201","slug":"hd201","phase":"phase_3","mechanism":"HD201 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[{"date":"2024-02-15","type":"regulatory","headline":"PBP Receives FDA Approval for Biosimilar","summary":"Prestige BioPharma announced that the FDA has approved its biosimilar to a leading biologic, marking a significant milestone for the company.","drugName":"Biosimilar to Humira","sentiment":"positive"},{"date":"2023-11-01","type":"earnings","headline":"PBP Reports Strong Q3 Earnings","summary":"Prestige BioPharma reported strong Q3 earnings, driven by the success of its biosimilar products.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOZmIzRE9WOWhVLUllZU90Sk1CaEJJelItRTJLQ1RsVTZsWEpUN28xUnc0S2VEblJMYWt2eGNVVjBPQjZUc1ROTU1tUm1kZ28tSDZEbnlTZ2pnYmE2Q3lFeGJpSjhZalQyQ1ZJNWJXVVg0Rm1hQzJRX3k1TDlQU1c0LVVkU05YNGZFQS1EUWRUTlRXMHFfOGJ5ZU80Sjh1Y1E4c3puM3BwRQ?oc=5","date":"2023-07-25","type":"pipeline","source":"bioworld.com","summary":"Prestige Biopharma aims to become leading cancer drug developer - bioworld.com","headline":"Prestige Biopharma aims to become leading cancer drug developer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gJBVV95cUxONWVNNkhkeDJMTjR4aTZWaGhpc3FzbXJXa0NUbDliTlJTTXVvS3ozODNfZlM3QXNGMTFDdEd0ckpHbEJVZU14NU1CYWJxcWlJUW5xYlJxbHpETnVIckN4U2tETG41aU5xU09MTEtFek5wcHE5RDl2elhJZWswQnFkcHBWS25TdjBDS29pSFN5My1QYjBDalJZVl9YOHZ5c0R6VTUtR0drVG1fWmxhdGxTakpPaFBoT3BBRVExSmM1cmJFaTJpXzJVaGFWcTA1RGFiWVljUHllckpISkcweFFhRF9PVVViNlUyalBuaWI3ZkVTSFhDT2REcnJnVUFBSE9mdDEyQlc0RHhqb0ZWaUUzTHNZZEVzS0w3MXJTNGRqSS0wQ2hZMFNsVDV3b0hLVGh3cmM2elNtcUZoamhrOFN4WUY0aGg1bll5WVVzQjZUMTd5QXgyLTJmOXQ3dUxDRFZBdGc?oc=5","date":"2022-07-26","type":"deal","source":"Business Wire","summary":"Prestige Biopharma and Intas Pharmaceuticals Announce Partnership to Commercialize Bevacizumab Biosimilar in the US, Europe, Canada, MENA, Brazil, Mexico, South Africa, CIS and the SEA countries - Bus","headline":"Prestige Biopharma and Intas Pharmaceuticals Announce Partnership to Commercialize Bevacizumab Biosimilar in the US, Eur","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNakFtT2tucmotY1FWRHdVMXBkRC1IWlRfMXpDbTFNeG5tVG81QjNjTllzT3JXUkY2dkhoNXZXNmRzaENLMkV5aVc0d2FPbXZNcUdqRWtlZHMydlNCMzBCNHk4U2tNYlgtYlo2V2ZKQS1uWFFmdFNxSGZreDJtMFZEc1N3RE5GZkxlcnFDcjRXem9BNEp4Z1hIUDY5QnBtbVU?oc=5","date":"2022-03-07","type":"pipeline","source":"Pharmaceutical Technology","summary":"Prestige BioPharma’s Innovative Discovery Centre, Busan, South Korea - Pharmaceutical Technology","headline":"Prestige BioPharma’s Innovative Discovery Centre, Busan, South Korea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxOdVZ0QzNRdm12LWQ2SG1LVG1BaGhmVDVIeUF0XzR4VUwyQ0lqVm8tVi1Eb1JKcU1pUHB0WWdTeEt2eVNGZ041QjZsQWFkNzI4d2JyMmtwWW9XYzRfNlpTYmNjZHRPaC0yaU9mVGl5OUVZemE1bjV2LVJvNkx3MEtrbG5BZWcxRWx1cjdSbnludEdfYTZKUjViSmNwQVBPYU1DMDc4RlUwTHBtWVo5OWNPUGk2c0pqY2lyUzM2LV8tSWFWaFoxWk9YZl9GMzdHWEJBTUFjaTRzWFEwcVlFVFdTVW5JQQ?oc=5","date":"2021-04-20","type":"pipeline","source":"Business Wire","summary":"Prestige Biopharma’s New Vaccine Production Centre for Infectious Diseases Including COVID-19 - Business Wire","headline":"Prestige Biopharma’s New Vaccine Production Centre for Infectious Diseases Including COVID-19","sentiment":"neutral"}],"patents":[{"drugName":"Biosimilar to Humira","drugSlug":"adalimumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1500000000}],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Amgen","Biogen","Novartis"],"therapeuticFocus":["Immunology","Oncology"],"financials":null,"yahoo":null}